The Effect of Rivaroxaban on Tunneled Cuffed Catheter Function in Hemodialysis Patients

Objective To investigate the effect of oral rivaroxaban on tunneled cuffed catheter function in maintenance hemodialysis patients. Methods A single-center retrospective cohort study design was adopted. Clinical data were collected from 40 patients who underwent maintenance hemodialysis using tunneled cuffed catheters as vascular access in our hospital from February to October 2025. The patients were divided into two groups based on whether they received oral rivaroxaban during dialysis: 20 patients in the observation group (oral rivaroxaban 10 mg/day) and 20 patients in the control group (no anticoagulant or antiplatelet medications). The incidence of catheter dysfunction, dialysis adequacy indicators, coagulation function, and bleeding events were retrospectively analyzed and compared between the two groups. Results The incidence of catheter dysfunction in the observation group was significantly lower than that in the control group(p < 0.01). The Kt/V values in the observation group were higher than those in the control group at all follow-up time points and remained stable(p < 0.05; p < 0.01). The mean blood flow in the observation group was significantly higher than that in the control group at all post-treatment time points(p < 0.05; p < 0.01). No significant differences were observed in coagulation function indicators (PT, APTT, Fib) before and after treatment or between the two groups (all p > 0.05). In the observation group, one patient experienced minor gingival bleeding, which resolved spontaneously without discontinuation of medication, while no bleeding events were observed in the control group. No severe bleeding or thromboembolic events occurred in either group. Conclusion Oral rivaroxaban (10 mg/day) effectively reduces the incidence of TCC dysfunction in MHD patients, contributes to maintaining dialysis adequacy, and shows a favorable safety profile without significant coagulation abnormalities or severe bleeding risk.